SPECIALTY QUANTITY LIMIT PROGRAM

XELODA (capecitabine)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

| Medication | FDA-recommended dosing | Standard Limit |
|---|--|------------------|
| Xeloda (capecitabine) 150 mg tablets | 1250 mg/m2 administered orally twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles *Maximum total daily dose of 5600 mg (2 tablets of 150 mg plus 5 tablets of 500 mg orally twice daily) for body surface area ≥ 2.18 m ² | 120 per 30 days* |
| Xeloda (capecitabine) 500 mg tablets | | 300 per 30 days* |

*For malignant tumor of the rectum and other compendial indications as listed in Micromedex DrugDex.

III. REFERENCES

- 1. Xeloda [package insert]. South San Francisco, CA: Genentech, Inc.; March 2015.
- 2. Micromedex Solutions [database online]. Ann Arbor, MI: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed August 7, 2017.

Specialty Quantity Limit Xeloda P2017.docx

© 2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

